O-Methylnordehydrobufotenine

O-Methylnordehydrobufotenine
Clinical data
Other names	O-Methyldehydrobufotenidine; 6-Methoxy-5-methyl-1,2,3,4,5-tetrahydropyrrolo[4,3,2-d,e]-quinoline
ATC code	None;
Identifiers
	IUPAC name 9-methoxy-7-methyl-2,7-diazatricyclo[6.3.1.04,12]dodeca-1(12),3,8,10-tetraene;
PubChem CID	11074453;
ChemSpider	9249602;
Chemical and physical data
Formula	C12H14N2O
Molar mass	202.257 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN1CCC2=CNC3=C2C1=C(C=C3)OC;
	InChI InChI=1S/C12H14N2O/c1-14-6-5-8-7-13-9-3-4-10(15-2)12(14)11(8)9/h3-4,7,13H,5-6H2,1-2H3; Key:PRPCWBYVLURNKE-UHFFFAOYSA-N;

O-Methylnordehydrobufotenine, also known as O-methyldehydrobufotenidine or as 6-methoxy-5-methyl-1,2,3,4,5-tetrahydropyrrolo[4,3,2-d,e]-quinoline, is a tricyclic cyclized tryptamine and analogue of 5-MeO-DMT and bufotenine. It produces hallucinogen-like effects in monkeys and rodents. However, although more potent than mescaline, O-methylnordehydrobufotenine was far less active than its open-chain analogue 5-MeO-DMT. The drug is not known to have been tested in humans. O-Methylnordehydrobufotenine was first described in the scientific literature by 1969.